Aurora Cannabis Stock (TSX:ACB) (OTC:ACBFF) - Investor Dashboard
Aurora Cannabis – Management Team
Terry Booth – CEO & Founder
Terry founded Aurora in 2013 when Health Canada announced the creation of the new MMPR program. Investing $2.5 million of his own capital in start-up funding Terry secured a 100 + acre parcel of land and began designing and building Aurora’s state of the art marijuana cultivation facility in Canada. To date he has served as President/CEO of 6 other highly successful companies including one that was awarded one of Canada’s top 50 fastest growing companies. Terry was instrumental in submitting and obtaining a Health Canada License to Produce Medical Marijuana for Aurora. Terry oversee’s the corporate strategy of the company including operations, sales, patient acquisition, doctor education programs, genetics development, regulatory affairs, facility expansion as well as the daily requirements of communicating with local and foreign capital markets and investors. Terry is a well-known community leader in his town of residence, Edmonton. There, he is known as a philanthropist and supporter of many worthy charitable causes such as early childhood development disabilities.
Steve Dobler, P. Eng – President
Steve Dobler began his distinguished career in 1990 upon obtaining his Professional Engineering designation from the University of Alberta. Steve has held numerous executive positions in successful private and public Canadian companies over the past 25 years where he was responsible for the implementation of project management, strategies, and overseeing all facets of various operations. Currently serving as President for Alberta’s largest safety codes permitting company, his focus is on customers, innovation, and improved operational efficiencies which directly led to significant company growth. In 2011, the company was included in the top 50 of Canada’s fastest growing companies. Harvesting the initial idea of Aurora, Steve sought out the challenge shortly after identifying its potential. Personally investing $2 million of start up capital, Steve is largely responsible for the $8.6 million the company has raised to date.
Glen Ibbott – Chief Financial Officer
Glen Ibbott is a seasoned senior healthcare executive with over 20 years’ experience providing financial leadership to various public entities, including management of Canadian and international capital market strategies, M&A, tax and finance, predominantly within the life sciences sector. An innovative, decisive, and insightful professional, he has excelled in delivering revenue and profitability growth, both domestically and internationally, strategy execution and shareholder value creation, including key contributions to numerous corporate transactions. Most recently, Mr. Ibbott was CFO at QLT Inc, a NASDAQ and TSX listed Biopharmaceutical Company and played a key role in QLT’s $500 million merger with Aegerion Pharmaceuticals to form Novelion Therapeutics. Prior to his time at QLT, Mr. Ibbott held various senior finance positions, including with globally operating companies such as Nordion, International Forest Products, Angiotech Pharmaceuticals, Aspreva Pharmaceuticals, and Inex Pharmaceuticals. Earlier in his career, he worked within the technology practice of KPMG. Mr. Ibbott completed MBAs at Cornell University and at Queen’s University, is a Canadian Chartered Professional Accountant (CPA, CA), as well as a US CPA, and holds a Bachelor’s of Business Administration from Simon Fraser University.
Allan Cleiren – Chief Operational Officer
Mr. Cleiren has nearly three decades of leadership experience in finance and operations management with both privately and publicly held companies in the life sciences, insurance, rail, construction, oil and gas service, and other sectors.. Most recently, Mr. Cleiren was COO with Jardine Lloyd Thompson Canada Inc. (JLT), one of the world’s leading providers of insurance, reinsurance and employee benefits related advice, brokerage and associated services. Prior to joining JLT, he served as Executive Vice President and formerly CFO for Universal Rail Systems Inc, and as Senior Vice President of Operations and CFO for Afexa Life Sciences. He is a member of the Board of Directors of Universal Rail Services Inc., Metalogic Inspection Services Inc., and is Chair of the Board for the Alberta Automobile Insurance Rate Board. Mr. Cleiren is a Chartered Professional Accountant (CPA, CA), holds a Bachelor of Commerce from the University of Alberta, and has a Diploma in Management Sciences from the Grant MacEwan College in Alberta. Mr. Cleiren also holds a ICD.D designation through the Institute of Corporate Directors.
Jason Dyck, Phd – Director and Head of Research Council
Dr. Dyck is a Professor in the Department of Pediatrics and the Director of the Cardiovascular Research Centre at the University of Alberta. He is also the co-director of the Alberta HEART, which is a province-wide program aimed at understanding and treating diastolic heart failure. He co-founded a successful University of Alberta spin-off company, currently holds more than 100 patents and has numerous collaborations with large pharmaceutical companies. His accomplishments in academic research, drug discovery and product/technology commercialization have contributed to Dr. Dyck being recognized as one of Canada’s Top 40 under 40 (awarded by the Caldwell Partners in 2007), which is “presented to exceptional Canadians under the age of 40 who are outstanding leaders in their chosen fields and who are shaping our country’s future”.
Adam Szweras – Director
Mr. Szweras has practiced corporate and securities law since 1996 and is a partner in the Securities Law Group of Fogler, Rubinoff LLP. In January 2006, Mr. Szweras founded Foundation Markets Inc. and FMI Capital Advisory Inc., a Toronto brokerage firm and merchant bank respectively, where he continues on in the role of Chairman. In Mr. Szweras’ law and banking practices, he focuses on working with emerging growth companies to develop and execute on their business plans, make acquisitions and to finance and list. Mr. Szweras works with companies in the mineral exploration sector, oil and gas, technology, and is a founder of a company developing marijuana and hemp oil and edible products for the US medical and recreational markets. Mr. Szweras is a board member or Corporate Secretary of several publicly listed companies where he plays a role as a key advisor and stakeholder.
Barry Fishman – Independent Director
Mr. Fishman, who will sit as an independent director, has a robust record of accomplishment as CEO of three major pharmaceutical companies, is a Certified Public Accountant (CPA), and has more than 30 years of experience in executive management, marketing and finance. Mr. Fishman is the CEO of international specialty pharmaceutical company Merus Labs (TSX: MSL) (NASDAQ: MSLI), where he has led the company to more than tripling sales and EBITDA over the last two fiscal years. Previously, he has served as CEO of both Teva Canada and Taro Canada, and is a past Chair of the Canadian Generic Manufacturers Association. He began his pharmaceutical career at Eli Lilly, where he advanced through several cross-functional leadership roles, including Vice President of Marketing. Mr. Fishman also has critical insights into the development of the cannabis sector, having previously served on the Board of Directors of Canopy Growth Corporation and Bedrocan Cannabis Corp.
Joseph del Moral – Independent Director
An innovator in new and emerging industries, Mr. del Moral is co-Founder and CEO of Canadian Cannabis Clinics (CCC). Mr. del Moral is also a co-founder of CanvasRx Inc., Canada’s leading cannabis outreach and counselling service provider, where he served as CEO until its acquisition by Aurora. Prior to his pioneering work in the cannabis industry, Mr. del Moral held several senior positions in the energy industry, including as founder of Newten Home Comfort, before its acquisition by Just Energy in 2010. He holds a B.Comm in Finance from McGill University.
Michael Singer – Independent Director
Michael Singer is an accomplished pharmaceutical industry executive and CFO consultant who has held a number of senior finance and governance roles. Michael is currently Chief Financial Officer for Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company developing treatments for people with rare diseases. Previously, he was CFO of Bedrocan Canada Inc. and successfully transitioned the company onto the TSXV in August 2014. Prior to Bedrocan, he served as CFO of Thallion Pharmaceuticals (TSXV: TLN) (previously Caprion Pharmaceuticals) from 2000 until its sale to BELLUS Health in 2013. Until July 2014, he served as Chairman of the Board of Warnex Inc. (TSXV: WNX.H) until successful completion of the company’s amalgamation with Diagnos Inc. (TSXV: ADK), where he continued to serve as an independent director until July 2016. Michael graduated from McGill University (1991) and is a Certified Professional Accountant – Certified General Accountant with the Ordre des CPA du Québec.
Significant Insider Ownership
Terry Booth, CEO
Steve Dobler, President
Jason Dyck, Director
New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.